These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34770992)

  • 1. Pyridinone Derivatives as Interesting Formyl Peptide Receptor (FPR) Agonists for the Treatment of Rheumatoid Arthritis.
    Crocetti L; Vergelli C; Guerrini G; Giovannoni MP; Kirpotina LN; Khlebnikov AI; Ghelardini C; Di Cesare Mannelli L; Lucarini E; Schepetkin IA; Quinn MT
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
    Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
    Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis.
    Odobasic D; Jia Y; Kao W; Fan H; Wei X; Gu R; Ngo D; Kitching AR; Holdsworth SR; Morand EF; Yang YH
    Int Immunopharmacol; 2018 Aug; 61():140-149. PubMed ID: 29879657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis.
    Kao W; Gu R; Jia Y; Wei X; Fan H; Harris J; Zhang Z; Quinn J; Morand EF; Yang YH
    Br J Pharmacol; 2014 Sep; 171(17):4087-96. PubMed ID: 24824742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
    Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
    Vergelli C; Khlebnikov AI; Crocetti L; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Cilibrizzi A; Quinn MT; Rossi P; Paoli P; Giovannoni MP
    Chem Biol Drug Des; 2021 Oct; 98(4):582-603. PubMed ID: 34148303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
    Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
    Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
    Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
    Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
    Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
    Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
    Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.
    Yi X; Tran E; Odiba JO; Qin CX; Ritchie RH; Baell JB
    Eur J Med Chem; 2024 Feb; 265():115989. PubMed ID: 38199163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
    Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Khlebnikov AI; Ye RD; Quinn MT
    Bioorg Med Chem; 2016 Jun; 24(11):2530-2543. PubMed ID: 27134116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.
    Khlebnikov AI; Schepetkin IA; Quinn MT
    Eur J Med Chem; 2010 Nov; 45(11):5406-19. PubMed ID: 20870313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardamonin (2',4'-dihydroxy-6'-methoxychalcone) isolated from Boesenbergia rotunda (L.) Mansf. inhibits CFA-induced rheumatoid arthritis in rats.
    Voon FL; Sulaiman MR; Akhtar MN; Idris MF; Akira A; Perimal EK; Israf DA; Ming-Tatt L
    Eur J Pharmacol; 2017 Jan; 794():127-134. PubMed ID: 27845065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective and Pain-Killer Effects of AMC3, a Novel N-Formyl Peptide Receptors (FPRs) Modulator, in Experimental Models of Rheumatoid Arthritis.
    Ferrara V; Toti A; Lucarini E; Parisio C; Micheli L; Ciampi C; Margiotta F; Crocetti L; Vergelli C; Giovannoni MP; Di Cesare Mannelli L; Ghelardini C
    Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37371936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N-Formyl Peptide Receptors and Rheumatoid Arthritis: A Dangerous Liaison or Confusing Relationship?
    Mormile I; Rossi FW; Prevete N; Granata F; Pucino V; de Paulis A
    Front Immunol; 2021; 12():685214. PubMed ID: 34220836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
    Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
    Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andrographolide ameliorates oxidative stress, inflammation and histological outcome in complete Freund's adjuvant-induced arthritis.
    Luo S; Li H; Liu J; Xie X; Wan Z; Wang Y; Zhao Z; Wu X; Li X; Yang M; Li X
    Chem Biol Interact; 2020 Mar; 319():108984. PubMed ID: 32061742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.
    Qin CX; May LT; Li R; Cao N; Rosli S; Deo M; Alexander AE; Horlock D; Bourke JE; Yang YH; Stewart AG; Kaye DM; Du XJ; Sexton PM; Christopoulos A; Gao XM; Ritchie RH
    Nat Commun; 2017 Feb; 8():14232. PubMed ID: 28169296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
    Cilibrizzi A; Quinn MT; Kirpotina LN; Schepetkin IA; Holderness J; Ye RD; Rabiet MJ; Biancalani C; Cesari N; Graziano A; Vergelli C; Pieretti S; Dal Piaz V; Giovannoni MP
    J Med Chem; 2009 Aug; 52(16):5044-57. PubMed ID: 19639995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.